Here, our novel findings document that in vivo topical application of BAY 11-7082 to HM, need not be precisely synchronized to bile exposure, in successfully blocking both the activation of NF-κB and deregulation of cancer-related genes and specific miRNA markers [13–19, 30–42], previously linked in vivo to pre-malignant changes and invasive squamous cell carcinogenesis [4, 7]. This evidence concerns the gene NFKB1 and cancer.